BeOne Medicines Ltd.

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

ONC$424.00+1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 5. Other Information

(c)

The following table describes for the quarterly period covered by this report each trading arrangement for the purchase or sale of Company securities adopted, modified orterminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement,” or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):

Name (Title)	Action Taken (Date of Action)	Type of Trading Arrangement	Nature of Trading Arrangement	Duration of Trading Arrangement	Aggregate Number of Securities
John V. Oyler(Co-Founder, Chief Executive Officer, and Chairman of the Board of Directors)	Adoption(March 12, 2025)	Rule 10b5-1 trading arrangement	Sale	July 8, 2026	Includes:(i)up to 100,000 ADSs to be sold by Mr. Oyler;(ii)up to such number of ADSs equal to the sum of (a) 43,538 ADSs underlying the vested Restricted Stock Units (“RSUs”) and (b) such net number of ADSs to be received upon future vesting of unvested RSU after sell-to-cover for withholding tax, to be sold by Mr. Oyler; and(iii)an additional number of ADSs to be sold by the Pan-Oyler Foundation in an amount as reasonably estimated to be sufficient to generate $800,000 in net proceeds, with the total number of ADSs to be determined based on the market price and related transaction costs.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.